George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding in Company

22 Sep 2017 14:01

RNS Number : 5998R
Silence Therapeutics PLC
22 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Silence Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 2,651,683*

 

HSBC Global Custody Nominee (UK) Limited 651,949*

State Street Nominees Limited 50,617*

Available on Request 7,076*

*denotes direct interest

 

Chase (GA Group) Nominees Limited 119,537

 

Chase Nominees Limited 55,444

 

Vidacos Nominees Limited 156,300

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

20/09/2017

6. Date on which issuer notified (DD/MM/YYYY):

21/09/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.28%

5.28%

69,991,624

Position of previous notification (if

applicable)

6.39%

6.39%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB00B9GTXM62

3,361,325

331,281

4.80%

0.48%

SUBTOTAL 8. A

3,692,606

5.28%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Aviva Investors Holdings Limited

5.27%

5.27%

Aviva Investors Global Services Limited

5.27%

5.27%

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Friends Provident

International Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

 

11. Additional informationxvi

This notification is prompted by a 5% to 4% change at Direct Interest Level (Box 8A)

 

Place of completion

Norwich, England

Date of completion

21 September 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGURABUPMGPP
Date   Source Headline
26th Nov 20217:00 amRNSUpdate on AIM Delisting
25th Nov 20215:30 pmRNSSilence Therapeutics
16th Nov 20217:00 amRNSThird Quarter 2021 Financial Results
11th Nov 20217:00 amRNSSilence to Present at Jefferies London Conference
10th Nov 20217:00 amRNSHolding(s) in Company
5th Nov 20217:00 amRNSNew Key Shareholder
1st Nov 20215:33 pmRNSResult of General Meeting
1st Nov 20214:49 pmRNSTotal Voting Rights
28th Oct 20214:02 pmRNSHolding(s) in Company
21st Oct 20211:30 pmRNSSilence Provides Pipeline Updates at 2021 R&D Day
15th Oct 20217:05 amRNSProposed Cancellation of Trading on AIM
15th Oct 20217:00 amRNSSilence and Hansoh Pharma Announce Collaboration
8th Oct 20217:00 amRNSBlock Listing Return
8th Oct 20217:00 amRNSTotal Voting Rights
7th Oct 20217:00 amRNSSilence Therapeutics to host R&D day
28th Sep 20217:00 amRNSChardan Genetic Medicines Conference Participation
8th Sep 20214:03 pmRNSHolding(s) in Company
8th Sep 20214:00 pmRNSHolding(s) in Company
1st Sep 20217:00 amRNSSilence Appoints Senior VP of BD, AM and NPD.
25th Aug 20217:00 amRNSSilence to Participate in Investor Conferences
12th Aug 20217:00 amRNSSilence Therapeutics Report Half-Year 2021 Results
6th Aug 202112:15 pmRNSHolding(s) in Company
6th Aug 202112:13 pmRNSHolding(s) in Company
5th Aug 20212:57 pmRNSTotal Voting Rights
15th Jul 20217:00 amRNSNotice of half year results
15th Jun 20215:54 pmRNSResults of Annual General Meeting
7th Jun 20217:00 amRNSSilence to present SL124 data at EHA
25th May 20217:00 amRNS$40m Payment from AstraZeneca for Collaboration
19th May 20217:00 amRNSPhase 1 Study in Healthy Volunteers Positive Data
12th May 20217:00 amRNSSilence attends RBC Global Healthcare Conference
7th May 20217:00 amRNSNotice of AGM
4th May 20217:00 amRNSSilence Support International Thalassemia Day
30th Apr 20214:12 pmRNSHolding(s) in Company
29th Apr 20215:58 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSFirst patient dosed in GEMINI II
28th Apr 20217:00 amRNSSilence Achieves Research Milestone Payment
27th Apr 20217:00 amRNSGrant of Employee Options
19th Apr 20217:00 amRNSPurchase of ADS and PDMR Shareholding
15th Apr 20217:00 amRNSPublication in Cardiovascular Research
7th Apr 20217:00 amRNSSilence to Present at Virtual Needham Conference
30th Mar 20216:13 pmRNSSilence Therapeutics Publication of Annual Report
30th Mar 20219:04 amRNSREPLACEMENT Silence Reports Full-year 2020 Results
30th Mar 20217:00 amRNSSilence Reports Full-year 2020 Results
26th Mar 20217:00 amRNSBlock Listing Application
4th Mar 20217:29 amRNSSilence presents at Barclays Healthcare Conference
1st Mar 20217:00 amRNSNotice of Annual Results
26th Feb 20217:00 amRNSSilence & Mallinckrodt Initiate Work on 3rd Target
24th Feb 20213:09 pmRNSHolding(s) in Company
22nd Feb 20217:00 amRNSSilence to Partake in March Investor Conferences
18th Feb 20217:00 amRNSSilence to present at SVB Leerink Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.